{"id":9038,"date":"2024-09-17T09:43:07","date_gmt":"2024-09-17T13:43:07","guid":{"rendered":"https:\/\/www.bluerocktx.com\/?p=9038"},"modified":"2024-09-17T09:44:03","modified_gmt":"2024-09-17T13:44:03","slug":"ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses","status":"publish","type":"post","link":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/","title":{"rendered":"Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses"},"content":{"rendered":"

Mucopolysaccharidoses are inherited metabolic disorders caused by the deficiency in lysosomal enzymes required to break down glycosaminoglycans. Accumulation of glycosaminoglycans leads to progressive, systemic degenerative disease. The central nervous system is particularly affected, resulting in developmental delays, neurological regression, and early mortality. Current treatments fail to adequately address neurological defects. Here we explore the potential of human induced pluripotent stem cell (hiPSC)-derived microglia progenitors as a one-time, allogeneic off-the-shelf cell therapy for several mucopolysaccharidoses (MPS). We show that hiPSC-derived microglia progenitors, possessing normal levels of lysosomal enzymes, can deliver functional enzymes into four subtypes of MPS knockout cell lines through mannose-6-phosphate receptor-mediated endocytosis in vitro. Additionally, our findings indicate that a single administration of hiPSC-derived microglia progenitors can reduce toxic glycosaminoglycan accumulation and prevent behavioral deficits in two different animal models of MPS. Durable efficacy is observed for eight months after transplantation. These results suggest a potential avenue for treating MPS with hiPSC-derived microglia progenitors.<\/p>\n","protected":false},"excerpt":{"rendered":"

Mucopolysaccharidoses are inherited metabolic disorders caused by the deficiency in lysosomal enzymes required to break down glycosaminoglycans. Accumulation of glycosaminoglycans leads to progressive, systemic degenerative disease. The central nervous system is particularly affected, resulting in developmental delays, neurological regression, and early mortality. Current treatments […]<\/p>\n","protected":false},"author":2,"featured_media":7701,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[56,74],"class_list":["post-9038","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-insights","tag-neurology","tag-cell-therapy"],"acf":[],"yoast_head":"\nReady-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses - BlueRock Therapeutics LP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses - BlueRock Therapeutics LP\" \/>\n<meta property=\"og:description\" content=\"Mucopolysaccharidoses are inherited metabolic disorders caused by the deficiency in lysosomal enzymes required to break down glycosaminoglycans. Accumulation of glycosaminoglycans leads to progressive, systemic degenerative disease. The central nervous system is particularly affected, resulting in developmental delays, neurological regression, and early mortality. Current treatments […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/\" \/>\n<meta property=\"og:site_name\" content=\"BlueRock Therapeutics LP\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-17T13:43:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T13:44:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/nature-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BlueRock Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BlueRock Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/\",\"url\":\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/\",\"name\":\"Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses - BlueRock Therapeutics LP\",\"isPartOf\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/nature-2.jpg\",\"datePublished\":\"2024-09-17T13:43:07+00:00\",\"dateModified\":\"2024-09-17T13:44:03+00:00\",\"author\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#primaryimage\",\"url\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/nature-2.jpg\",\"contentUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/nature-2.jpg\",\"width\":900,\"height\":1000,\"caption\":\"nature communications logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.bluerocktx.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bluerocktx.com\/#website\",\"url\":\"https:\/\/www.bluerocktx.com\/\",\"name\":\"BlueRock Therapeutics LP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bluerocktx.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\",\"name\":\"BlueRock Therapeutics\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"caption\":\"BlueRock Therapeutics\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses - BlueRock Therapeutics LP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/","og_locale":"en_US","og_type":"article","og_title":"Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses - BlueRock Therapeutics LP","og_description":"Mucopolysaccharidoses are inherited metabolic disorders caused by the deficiency in lysosomal enzymes required to break down glycosaminoglycans. Accumulation of glycosaminoglycans leads to progressive, systemic degenerative disease. The central nervous system is particularly affected, resulting in developmental delays, neurological regression, and early mortality. Current treatments […]","og_url":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/","og_site_name":"BlueRock Therapeutics LP","article_published_time":"2024-09-17T13:43:07+00:00","article_modified_time":"2024-09-17T13:44:03+00:00","og_image":[{"width":900,"height":1000,"url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/nature-2.jpg","type":"image\/jpeg"}],"author":"BlueRock Therapeutics","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BlueRock Therapeutics","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/","url":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/","name":"Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses - BlueRock Therapeutics LP","isPartOf":{"@id":"https:\/\/www.bluerocktx.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#primaryimage"},"image":{"@id":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/nature-2.jpg","datePublished":"2024-09-17T13:43:07+00:00","dateModified":"2024-09-17T13:44:03+00:00","author":{"@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057"},"breadcrumb":{"@id":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#primaryimage","url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/nature-2.jpg","contentUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/nature-2.jpg","width":900,"height":1000,"caption":"nature communications logo"},{"@type":"BreadcrumbList","@id":"https:\/\/www.bluerocktx.com\/ready-to-use-ipsc-derived-microglia-progenitors-for-the-treatment-of-cns-disease-in-mouse-models-of-neuropathic-mucopolysaccharidoses\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bluerocktx.com\/"},{"@type":"ListItem","position":2,"name":"Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses"}]},{"@type":"WebSite","@id":"https:\/\/www.bluerocktx.com\/#website","url":"https:\/\/www.bluerocktx.com\/","name":"BlueRock Therapeutics LP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bluerocktx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057","name":"BlueRock Therapeutics","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","caption":"BlueRock Therapeutics"}}]}},"_links":{"self":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/9038"}],"collection":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/comments?post=9038"}],"version-history":[{"count":2,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/9038\/revisions"}],"predecessor-version":[{"id":9040,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/9038\/revisions\/9040"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media\/7701"}],"wp:attachment":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media?parent=9038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/categories?post=9038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/tags?post=9038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}